Technical Steering Adviser — Performance Evidence and Release Confidence

The mandate

A technical steering forum receives performance summaries for retail and healthcare products but finds it difficult to judge how much confidence those summaries warrant. Test teams may have met the stated targets while exercising a workload that omits a material operating behaviour. The adviser will examine the connection between the proposed release conditions, the work actually tested and the claims made to reviewers, helping the forum ask a better question before it accepts broad assurance.

The retainer runs for nine months from 26 October 2026, protecting three days monthly and including one monthly technical steering session. Three planned onsite sessions are covered by the same fee; other discussions are remote. A pre-read critique and evidence conversation form the regular cadence. Off-cycle questions receive acknowledgement within one working day and a written technical observation within three working days after the complete test and proposed-release records arrive.

The standing issue is the reach of the evidence. A large test volume cannot compensate for a missing transaction sequence, and a stable run may say little about an operating condition that was held artificially constant. The adviser will challenge which populations, time patterns and failure assumptions the result covers. Where performance teams need further experiments, the advice will identify the unanswered question and its decision consequence without prescribing a complete implementation or taking ownership of the engineering backlog.

This specialist appointment gives no line authority to the adviser and assigns no executive responsibility for engineering or release decisions. Existing product and platform leaders own actions, the release authority accepts any limitation and qualified healthcare owners retain clinical interpretations. No board membership or fiduciary position is offered. The adviser does not approve deployment, certify patient safety or guarantee that an untested production condition will behave like a controlled exercise.

The chair reviews renewal in month eight, with the governing technical sponsor approving a new written scope and a term no longer than twelve months. Up to two other advisory retainers are permitted if the reserved capacity remains workable. Relationships with competing products, testing vendors or service providers whose evidence is under review require disclosure before access. Topic restriction, recusal or termination follows where a commercial interest prevents neutral evaluation of the performance claim.

What you will own

• Challenge the relationship between proposed release conditions and tested workloads, identifying omitted sequences or populations that materially limit what the supplied performance result can support.
• Examine the assumptions held constant during testing, asking which dependency, data or timing conditions may change in operation and require a narrower confidence statement.
• Shape steering questions that connect a technical evidence gap to an actual release choice, distinguishing further information needed from an engineering action the adviser cannot direct.
• Probe headline latency and throughput claims for incomplete outcome definitions, helping reviewers recognise when a successful technical response does not establish a completed operational task.
• Recommend explicit wording for material performance limitations and uncertainty, preserving the difference between observed results, extrapolation and an operating assumption accepted by the release owner.
• Advise on the sufficiency of follow-up experiments proposed by engineering, testing whether they answer the missing question rather than merely add another favourable run to the pack.
• Review successive steering papers against earlier challenge points, highlighting unresolved assumptions while leaving test execution, clinical interpretation and final deployment authority with the responsible owners.

Candidate qualifications

• Demonstrate seven or more years of performance architecture or engineering practice, including retail, healthcare or comparable product workflows. Describe a performance conclusion whose apparent strength depended on an incomplete workload assumption, the omitted behaviour you identified and the recommendation that changed. The forum needs personal analytical judgement about the evidence, not attendance at a review where someone else established the limitation.
• Be able to assess experiment coverage, outcome definitions and confidence limits using the platform's available records. Explain how you distinguish a repeatable finding from an extrapolation or a convenient test condition, and how you decide which uncertainty matters to the release choice. Specific vendor tools or coding stacks are not prescribed; the required expertise is performance reasoning that another technical reviewer can examine and challenge.
• Bring constructive technical communication through architecture reviews, peer challenge or specialist advice. Provide a case where you stated an unwelcome evidence gap without either overstating the risk or giving reassurance the data could not support. You must respect product, engineering and qualified healthcare decision boundaries, identifying the right owner when the question requires functional acceptance, clinical judgement or implementation authority.
• Protect three monthly days, the steering cadence and the three-working-day written observation window. Disclose relevant product, testing-vendor and service-provider interests and describe how you would handle a paper affecting another appointment. Evidence should show disciplined information use and a clear separation between independent advice and paid test delivery, with no incentive tied to release approval or a favourable assurance statement.

Application

Applications for this mandate are received in one way only: through the India Board Terminal's application process. It is automated end to end. Your Executive Passport travels to the mandate holder in its confidential form, your answers to the three questions below are read before anything else in your file, and every stage that follows is recorded on your applications page.

There is no address to write to and no intermediary to call. The mandate holder reads what the Terminal delivers and nothing else, which is what keeps the process the same for every applicant and keeps your name out of it until you release it. Applications close on 12 October 2026. Mandate reference CVU-ADV-2026-IND-085.